Key terms
About COR
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest COR news
Yesterday
5:19am ET
Cencora: A Balanced View Amidst Mixed Financial Indicators – Hold Rating Maintained
Yesterday
5:17am ET
Cencora Outperforms in Q2: A Buy Rating with Room to Grow
Yesterday
3:49am ET
Cencora (COR) Receives a Buy from Barclays
May 01
6:42am ET
Cencora Schedules Fiscal Quarter Results Discussion Webcast
May 01
6:32am ET
Cencora raises FY24 adjusted EPS view to $13.30-$13.50 from $13.25-$13.50
May 01
6:31am ET
Cencora reports Q2 adjusted EPS $3.80, consensus $3.69
Apr 30
7:39pm ET
AUSF: This ETF Is Enticing in a Volatile Market
Apr 30
5:45pm ET
Cardinal Health Stock (NYSE:CAH): Dip Creates Long-Term Opportunity
Apr 29
9:33pm ET
Cencora price target raised to $280 from $265 at Citi
Apr 24
4:46am ET
Cencora (COR) Receives a Buy from Barclays
Apr 16
9:56am ET
Early notable gainers among liquid option names on April 16th
Mar 13
6:41am ET
Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)
Mar 13
6:30am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR) and Clearside Biomedical (CLSD)
Mar 12
9:03am ET
Cencora Announces CEO Change, Reaffirms 2024 Financial Outlook
Mar 12
8:39am ET
Cencora backs FY24 adjusted EPS view $13.25-$13.50 from $12.70-$13.00
Mar 12
8:36am ET
Cencora CEO Steven Collis to retire, Robert Mauch to succeed
Feb 26
7:10am ET
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
Feb 26
6:20am ET
Cencora initiated with an Outperform at Leerink
Feb 14
10:01am ET
FTC probing drug distributors over low supplies of chemotherapies, WSJ reports
Feb 10
4:29am ET
Cencora Significant Share Sale Alters Ownership Stake
Feb 10
4:28am ET
Cencora Buys Back Shares to Boost Shareholder Value
Feb 08
4:29am ET
Cencora Receives Legal Opinion on Note Validity
Feb 08
4:29am ET
Cencora Closes Notes Offering, Attracts Investor Interest
Feb 08
4:29am ET
Cencora Establishes New Direct Financial Commitment
Feb 08
4:29am ET
Cencora Secures $500M in Senior Notes Offering
Feb 07
6:28pm ET
Cencora announces common share repurchase from Walgreens Boots Alliance
Feb 05
1:20pm ET
Analysts Conflicted on These Healthcare Names: Cencora (COR) and Morphosys Ag (MOR)
Feb 05
1:08pm ET
Cencora price target raised to $235 from $213 at Wells Fargo
Feb 05
7:44am ET
Cencora price target raised to $224 from $192 at Mizuho
No recent press releases are available for COR
COR Financials
Key terms
Ad Feedback
COR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
COR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
